These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 31105973)

  • 1. Treating ischaemic stroke with intravenous tPA beyond 4.5 hours under the guidance of a MRI DWI/T2WI mismatch was safe and effective.
    Bai QK; Zhao ZG; Lu LJ; Shen J; Zhang JY; Sui HJ; Xie XH; Chen J; Yang J; Chen CR
    Stroke Vasc Neurol; 2019 Mar; 4(1):8-13. PubMed ID: 31105973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome of multimodal MRI-guided intravenous thrombolysis in patients with stroke with unknown time of onset.
    Zhao J; Zhao H; Li R; Li J; Liu C; Lv J; Li Y; Liu W; Ma D; Hao H; Xiao X; Liu J; Yin Y; Liu R; Yu Q; Wei Y; Li P; Wang Y; Wang R
    Stroke Vasc Neurol; 2019 Mar; 4(1):3-7. PubMed ID: 31105972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early and continuous neurologic improvements after intravenous thrombolysis are strong predictors of favorable long-term outcomes in acute ischemic stroke.
    Yeo LL; Paliwal P; Teoh HL; Seet RC; Chan BP; Wakerley B; Liang S; Rathakrishnan R; Chong VF; Ting EY; Sharma VK
    J Stroke Cerebrovasc Dis; 2013 Nov; 22(8):e590-6. PubMed ID: 23954601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple hypointense vessels on susceptibility-weighted imaging predict early neurological deterioration in acute ischaemic stroke patients with severe intracranial large artery stenosis or occlusion receiving intravenous thrombolysis.
    Liu YL; Yin HP; Qiu DH; Qu JF; Zhong HH; Lu ZH; Wang F; Liang MQ; Chen YK
    Stroke Vasc Neurol; 2020 Dec; 5(4):361-367. PubMed ID: 32586972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should IV Thrombolysis be given in Patients with Suspected Ischemic Stroke but Unknown Symptom Onset and Without Diffusion-Weighted Imaging Lesion? - Results of a Case-Control Study.
    Seyhan M; Mackenrodt D; Gunreben I; Müllges W; Haeusler KG; Pham M; Kleinschnitz C; Kraft P
    J Stroke Cerebrovasc Dis; 2020 Feb; 29(2):104515. PubMed ID: 31786042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Intravenous administration of a tissue plasminogen activator beyond 3 hours of the onset of acute ischemic stroke--MRI-based decision making].
    Kakuda W; Abo M
    Brain Nerve; 2008 Oct; 60(10):1173-80. PubMed ID: 18975605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Migraine History: A Predictor of Negative Diffusion-Weighted Imaging in IV-tPA-Treated Stroke Mimics.
    Lima J; Mehta T; Datta N; Bakradze E; Staff I; Beland D; Nouh A
    J Stroke Cerebrovasc Dis; 2019 Nov; 28(11):104282. PubMed ID: 31401044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of post thrombolytic intracerebral hemorrhage volume on 90-day outcomes in acute ischemic stroke patients.
    Gillani SA; Ma X; Huang Y; Bains NK; Fakih R; Siddiq F; French BR; Gomez CR; Lyden PD; Qureshi AI
    J Stroke Cerebrovasc Dis; 2024 Nov; 33(11):107962. PubMed ID: 39191317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring intravenous recombinant tissue plasminogen activator thrombolysis for acute ischemic stroke with diffusion and perfusion MRI.
    Schellinger PD; Jansen O; Fiebach JB; Heiland S; Steiner T; Schwab S; Pohlers O; Ryssel H; Sartor K; Hacke W
    Stroke; 2000 Jun; 31(6):1318-28. PubMed ID: 10835451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with intravenous alteplase in ischaemic stroke patients with onset time between 4.5 and 24 hours (HOPE): protocol for a randomised, controlled, multicentre study.
    Luo Z; Zhou Y; He Y; Yan S; Chen Z; Zhang X; Chen Y; Tong LS; Zhong W; Hu H; Zhang K; Yang J; Campbell BCV; Lou M
    Stroke Vasc Neurol; 2024 Jun; 9(3):318-323. PubMed ID: 37527920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Who may benefit from lower dosages of intravenous tissue plasminogen activator? Results from a cluster data analysis.
    Dong Y; Han Y; Shen H; Wang Y; Ma F; Li H; Wang Y; Dong Q
    Stroke Vasc Neurol; 2020 Dec; 5(4):348-352. PubMed ID: 32611728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.
    Kono S; Deguchi K; Morimoto N; Kurata T; Deguchi S; Yamashita T; Ikeda Y; Matsuura T; Narai H; Omori N; Manabe Y; Yunoki T; Takao Y; Kawata S; Kashihara K; Abe K
    J Stroke Cerebrovasc Dis; 2013 Apr; 22(3):190-6. PubMed ID: 21968092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of intravenous recombinant tissue plasminogen activator in mild ischaemic stroke: a meta-analysis.
    You S; Saxena A; Wang X; Tan W; Han Q; Cao Y; Liu CF
    Stroke Vasc Neurol; 2018 Mar; 3(1):22-27. PubMed ID: 29600004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different Mismatch Concepts for Magnetic Resonance Imaging-Guided Thrombolysis in Unknown Onset Stroke.
    Scheldeman L; Wouters A; Boutitie F; Dupont P; Christensen S; Cheng B; Ebinger M; Endres M; Fiebach JB; Gerloff C; Muir KW; Nighoghossian N; Pedraza S; Simonsen CZ; Thijs V; Thomalla G; Lemmens R;
    Ann Neurol; 2020 Jun; 87(6):931-938. PubMed ID: 32227638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant Tissue-Type Plasminogen Activator Study of Wake-Up Ischemic Strokes Guided by Rapid MRI.
    Guo C; Bai Q; Zhao Z; Zhang J
    Cerebrovasc Dis; 2019; 48(1-2):85-90. PubMed ID: 31587000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data.
    Thomalla G; Boutitie F; Ma H; Koga M; Ringleb P; Schwamm LH; Wu O; Bendszus M; Bladin CF; Campbell BCV; Cheng B; Churilov L; Ebinger M; Endres M; Fiebach JB; Fukuda-Doi M; Inoue M; Kleinig TJ; Latour LL; Lemmens R; Levi CR; Leys D; Miwa K; Molina CA; Muir KW; Nighoghossian N; Parsons MW; Pedraza S; Schellinger PD; Schwab S; Simonsen CZ; Song SS; Thijs V; Toni D; Hsu CY; Wahlgren N; Yamamoto H; Yassi N; Yoshimura S; Warach S; Hacke W; Toyoda K; Donnan GA; Davis SM; Gerloff C;
    Lancet; 2020 Nov; 396(10262):1574-1584. PubMed ID: 33176180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of magnetic resonance angiography-diffusion weighted imaging mismatch in hyperacute cerebral infarction.
    Deguchi I; Takeda H; Furuya D; Dembo T; Nagoya H; Kato Y; Ito Y; Fukuoka T; Maruyama H; Tanahashi N
    J Stroke Cerebrovasc Dis; 2012 Feb; 21(2):108-13. PubMed ID: 20851627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presence of deep white matter lesions on diffusion-weighted imaging is a negative predictor of early dramatic improvement after intravenous tissue plasminogen activator thrombolysis.
    Kawano H; Hirano T; Inatomi Y; Terasaki T; Yonehara T; Uchino M
    Cerebrovasc Dis; 2010 Aug; 30(3):230-6. PubMed ID: 20606424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and magnetic resonance imaging predictors of very early neurological response to intravenous thrombolysis in patients with middle cerebral artery occlusion.
    Apoil M; Turc G; Tisserand M; Calvet D; Naggara O; Domigo V; Baron JC; Oppenheim C; Touzé E
    J Am Heart Assoc; 2013 Dec; 2(6):e000511. PubMed ID: 24308937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Negative diffusion-weighted imaging after intravenous tissue-type plasminogen activator is rare and unlikely to indicate averted infarction.
    Freeman JW; Luby M; Merino JG; Latour LL; Auh S; Song SS; Magadán A; Lynch JK; Warach S; Hsia AW
    Stroke; 2013 Jun; 44(6):1629-34. PubMed ID: 23572476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.